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Fabry disease is an X-linked lysosomal disor-
der that leads to excessive deposition of neutral gly-
cosphingolipids in the vascular endothelium of sev-
eral organs and in epithelial and smooth muscle cells. 
Disease is characterized by the accumulation of the 
glycosphingolipid substrate, ceramide trihexoside and 
ceramide dihexoside in tissues. Progressive endotheli-
al accumulation of glycosphingolipids accounts for the 
associated clinical abnormalities of skin, eye, kidney, 
heart, brain, and peripheral nervous system. 
When young patients present with signs and 
symptoms of a stroke, along with a history of skin le-
sions, renal insuffi  ciency or failure, and heart attacks, 
Fabry disease is a consideration. Clinical manifesta-
tions of Fabry disease comprise chronic pain, kidney 
impairment, skin lesions, ocular opacities, vascular 
deterioration, stroke and cardiac deficiencies leading 
to premature mortality.
Fabry disease is uncommon, although research 
suggests that Fabry mutations may be more frequent 
in cryptogenic stroke patients. Aggressive eff orts to 
diagnose the etiology of stroke are necessary to plan 
secondary prevention strategies. Traditional second-
ary stroke prevention strategies are still necessary. 
Treatment strategies involve combined eff orts from 
multiple specialties. Th e diagnosis and care of these 
patients usually is best handled at tertiary care centers. 
Enzyme replacement therapy has recently become ac-
cessible. Agalasidase is recombinant form of the hu-
man enzyme α-Gal A, which is deficient in patients 
with Fabry disease. Data from clinical trials show a 
decrease in globotriaosylceramide levels following 
enzyme replacement, reversal in lipid tissue storage, 
stabilized or improved renal and cardiac function, and 
reduction or relief of neuropathic pain. 
